14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ELDN vs MIRM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Mirum Pharmaceuticals, Inc. (MIRM) captures the overall head-to-head institutional edge over Eledon Pharmaceuticals, Inc. (ELDN) on higher Unified Composite conviction (51.1/100 HOLD vs. 44.3/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while ELDN wins 3–2 across the 6-pillar growth and valuation breakdown. ELDN trades at $1.78 (5.4x Forward P/E, 0.0% operating margin) versus MIRM at $96.13 (N/M Forward P/E, -21.6% operating margin).
Growth vs. Quality Trade-Off: MIRM earns the overall head-to-head edge with a stronger Unified Composite Score (51.1/100 HOLD vs. ELDN 44.3/100 HOLD) and 0.86β · 48% Vol risk profile, whereas ELDN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: ELDN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.8); meanwhile MIRM trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 62.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELDN vs MIRM. Trailing 12-month operating profitability (ELDN 0.0% vs MIRM -21.6%) and valuation multiples (ELDN 5.4x vs MIRM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $6.2B market capitalization and -21.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ELDN vs MIRM Key Questions & Quantitative Answers
As of Nov 20, 2026, Mirum Pharmaceuticals, Inc. (MIRM) captures the overall head-to-head institutional edge over Eledon Pharmaceuticals, Inc. (ELDN) on higher Unified Composite conviction (51.1/100 HOLD vs. 44.3/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while ELDN wins 3–2 across the 6-pillar growth and valuation breakdown. ELDN trades at $1.78 (5.4x Forward P/E, 0.0% operating margin) versus MIRM at $96.13 (N/M Forward P/E, -21.6% operating margin). Growth vs. Quality Trade-Off: MIRM earns the overall head-to-head edge with a stronger Unified Composite Score (51.1/100 HOLD vs. ELDN 44.3/100 HOLD) and 0.86β · 48% Vol risk profile, whereas ELDN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ELDN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.8); meanwhile MIRM trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 62.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MIRM leads the Growth & Scale pillar: ELDN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MIRM at +39.6% YoY revenue growth and +0.0% YoY earnings growth on $671M TTM revenue (81.7% gross margin, -21.6% operating margin). On trailing 12-month operating scale, ELDN generates N/A in USD-normalized revenue versus $671M for MIRM. In operating R&D and SG&A reinvestment, ELDN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MIRM.
ELDN screens cheaper on headline valuation multiples. ELDN trades at 5.4x Forward P/E, 5.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MIRM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 10.0x EV/Revenue (-46.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ELDN (-105.7% ROE) versus MIRM (-760.0% ROE) capital efficiency.
In options market volatility and institutional positioning, ELDN carries 113.7% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.78β · 116% Vol realized risk). By comparison, MIRM carries 109.3% implied volatility (15th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.86β · 48% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.